We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Amryt Pharma Plc | LSE:AMYT | London | Ordinary Share | GB00BKLTQ412 | ORD 6P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 143.00 | 151.00 | 170.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
22/10/2019 10:33 | Thanks BS I see that Amryt are at both the Shares Mag and Proactive investor meetings this week (tomorrow and Thursday), so I will probably go along to one or both On the subject of CVRs, I hold a few Amryt shares on a certificate and a few in the ISA, I have now received 3 additional certificates for the CVRs, but there is nothing showing in my ISA account or in notifications to tell me that the CVRs have been allocated and need to be transferred out. Lastly, I found this short video on Rhys, a 14 year old boy with very severe EB on BBC iplayer. It was first shown on Sept 23rd, but I am not sure whether it has been posted here before: | timbo003 | |
21/10/2019 18:33 | Link below to latest presentation from Kieran Rooney | bermudashorts | |
21/10/2019 10:43 | From the lse bb: Bronxville Posts: 1,265 Price: 116.50 No Opinion AMRYT'S baby Today 08:42 Irish scientists announce breakthrough on genetic skin disease 21/10/2019 - 06:36 By Press Association Irish researchers have announced a breakthrough in the search for a cure for a painful skin disease. Epidermolysis bullosa (EB) is a genetic condition in which sufferers lack a vital protein responsible for binding skin. This results in painful blisters – both internal and external – from the slightest knock or bump. The disease affects approximately 300 people in Ireland. Researchers at University College Dublin (UCD) say they have now produced a solution that uses gene therapy to repair bad cells. The best part of this therapy is that it would not involve painful skin grafting procedures or risks associated with viral treatments in delivering functioning genes to the skin The breakthrough has the potential to provide a permanent cure for patients with Recessive Dystrophic EB, one of the most severe sub-types of the disease, for which no treatment currently exists. The concept has been pioneered by Professor Wenxin Wang, who has been carrying out research into EB for the past 10 years, with assistance from the charity Debra Ireland. Dr Jonathan O’Keeffe Ahern, one of the leading gene therapy researchers in Professor Wang’s team, said one of the greatest benefits of the solution is that it removes the need for painful surgery. “The best part of this therapy is that it would not involve painful skin grafting procedures or risks associated with viral treatments in delivering functioning genes to the skin,” he said. Gene therarpy researchers Dr Irene Lara-Saez and Dr Jonathan O’Keeffe Ahern (Shane O’Neill/PA) “We call this the Fed Ex of gene editing – we deliver a biological solution using a simple carrier system. “Rather like using a postcode, we can send in a genetic scissors to cut out the non-functioning part of a gene and then the repaired cells know to fill that space and permanently repair the gene. “We would not need to even take the patient cells for skin grafting. The gel would be applied, absorbed and go to work. “We have seen some promising results in the lab. With further research, we could expand this to other EB types and even other genetic conditions. “We are in the process of forming our own spin-out company to continue to develop this technology and take it to the next step, a clinical trial.” Debra Ireland head of research Dr Sinead Hickey (centre) with Dr Jonathan O’Keeffe Ahern and Dr Irene Lara-Saez, of the University College Dublin gene therapy research team (Shane O’Neill/PA) Debra Ireland provides day-to-day help and support for EB patients and their families and also works to find better treatments and possible cures for EB. This week (October 21-27) is National EB Awareness Week and the charity is asking the public to get involved by wearing a butterfly tattoo to raise awareness for this rare disease and funds for further . Cionnathagad Posts: 51 Price: 116.50 No Opinion RE: AMRYT'S baby Today 09:49 Sounds good. Amryt has licensed this therapy as AP103.I just picked up another 4k to have a nice round figure. Bronxville Posts: 1,265 Price: 116.50 No Opinion RE: AMRYT'S baby Today 10:05 Here's hoping we get fast track approval.. That's my 10k earlier...I've too much tied up in BOI at the moment to buy more...(: Bronxville Posts: 1,265 Price: 116.50 No Opinion RE: AMRYT'S baby Today 10:22 It sounds to me like this therapy could be used for other skin conditions.. I'm wondering about Melanoma? Diamondstar might know.. | papillon | |
21/10/2019 08:38 | University College Dublin have found a cure for Recessive Dystrophic EB. Thank God. Heard it on the radio just now. It's EB awareness week . | chica1 | |
20/10/2019 17:52 | 90 days could take us into December, ab321. Obviously Cathal Friel was being more optimistic. Was his optimistic forecast nothing more than just wishful thinking? 4 share trades Wednesday for 45 shares. 4 trades Thursday for 3862 shares. 2 trades Friday for 1888 shares. So just 4795 shares traded over 3 days at a total cost of £6425 and 20p. This for a company with a Mkt Cap of around £180m. The MM's will soon be passing round the hat and the begging bowl! LOL. | papillon | |
20/10/2019 14:19 | Admission doc says within 90 days of deal closing, hopefully sooner rather than later | alphabravo321 | |
18/10/2019 12:02 | Well alphabravo, Cathal Friel recently predicted that new AMYT would list on Nasdaq in October. Only 9 trading days left if Friel's prediction is to come true. | papillon | |
17/10/2019 14:22 | Are we expecting much news on the 23rd? | tiananmen | |
16/10/2019 20:57 | I think AIM is the problem, roll on US listing | alphabravo321 | |
16/10/2019 19:59 | Just 4 trades today. All sells. All very, very, small. 2 for just 3 shares each both @ 115.07p, 1 for 32 shares and another 1 for 7 shares both @ 115p. So a grand total of just 45 shares and cash proceeds of a miserable 51 quid and 25p. Simply AMAZINGLY low turnover for a company with a Mkt Cap of circa 180m. Admittedly there is a relatively small free float percentage, but even so today's volume is pitifully small for a company with a Mkt Cap of circa 180m. | papillon | |
16/10/2019 12:58 | You've sold all your shares then Pap? | tiananmen | |
16/10/2019 12:14 | just 3 trades so far today. All 3 are tiny. 2 sells of 3 shares and 1 sell of 32 shares. TOTAL shares traded just 38 shares!!!!!!!!!!!!!! | papillon | |
15/10/2019 15:43 | Some big trades today including a large buy (50k @ 115p). Beginning to look like the share price bottomed last week? Possible. Surely we should be getting the Nasdaq listing news soon? Bring it on! | papillon | |
11/10/2019 11:24 | A return to the early Septembers low of circa 103 seems possible in the short term. | papillon | |
10/10/2019 22:26 | Very Sensible post on the lse by gameangler: gameangler Posts: 101 Price: 113.00 No Opinion RE: Thoughts... Today 22:33 Novelion could arrange for Amryt Shares to be placed in the market (unless they have a timing constraint), and the proceeds together with the cash passed to their shareholders. Alternatively there could be, pro rata transfers in specie to Novelion shareholders. The majority of shareholder are funds, so the directors may move with the majority preference. We will have to wait and see. Not withstanding how they dispose of these shares, I wouldn't follow Amryt share price as a guide to its value at this time. The $60m fundraising shares( without CVRs), were bought by insiders, including Private Equity Funds, at £1.44 a share on 25th Sept. This is an informed valuation of the new Amryt. Since 20th Sep, Amryt shares have been falling from the high point of £1.41 when CVRs were created. Some shareholders could be liquidating holdings to use the funds elsewhere, but retaining their CVRs. Expect some volatility until these issues play out and we get a bit more certainty. >>>>> "Since 20th Sep, Amryt shares have been falling from the high point of £1.41 when CVRs were created. Some shareholders could be liquidating holdings to use the funds elsewhere, but retaining their CVRs" Credit where credit is due. mdalos got it spot on. Hats off to mdalos. He sold his AMYT shares, but has got the CVR's (or so he says). Me? I did the right thing in selling 500 shares, but I should have sold more and I was too quick to buy that 750 shares. I guessed that the share price would fall back (hence the 500 sell, but should have sold more), but have failed to pick the bottom (hence poorly judged 750 buy). PS gameangler says "I wouldn't follow Amryt share price as a guide to its value at this time. The $60m fundraising shares( without CVRs), were bought by insiders, including Private Equity Funds, at £1.44 a share on 25th Sept. This is an informed valuation of the new Amryt." A word of caution on that "informed" 144p valuation. After all the 3 funds managed by Neil Woodford must have thought 400p was a fair valuation for KIE because they backed the placing at that price big time. However within months the KIE share price was sub 100p (it's currently around 110p). Funds can and do get it wrong, just like PI's | papillon | |
10/10/2019 16:38 | chica, Bermudashorts provides the link to the "Liquidation Process" quoted in cadburyhill's post. Obviously Bermudashorts and cadburyhill have done their homework on Novelion, AMYT & Aegerion. I, on the other hand, profess ignorance!! I'm just a mug punter checking the AMYT share price daily!!!!!!!!!!!!!!! | papillon | |
10/10/2019 16:28 | chica. Read cadburyhill's last post timed at 15:40 which was a reply to Bronxville. Here's part of that cadburthill post. Bronxville by the way thanked cadburyhill for their input. "exactly...so novelion holders wait for the redistribution of the proceeds from the sale of the amyrt stake on the liquidation of novelion. see below. in fact, it may well be simpler than i've thought it was: perhaps the novelion stake is simply an overhang that needs to be cleared asap. but i still suspect that if novelion is or was trading OTC at a worthwhile discount to the proceeds of an amryt's stake's sale and its redistribution to novelion shareholders, then this is a trade that a special sits fund will try and exploit. "The Liquidation Proposal follows the previously announced completion of the acquisition by Amryt Pharma plc (“Amryt” | papillon | |
10/10/2019 16:24 | Think the plan for some time has been for Novelion to be wound up on completion of the sale of Aegerion. Anyway, here is press release from last week:- | bermudashorts | |
10/10/2019 16:16 | You're right chaps, hadn't noticed that in the HL email but it does say they have to be moved out of the ISA within 30 days. It says further information will be provided about how this works but heard nothing yet. I guess they'll just get transferred into a standard share trading account. | webpax | |
10/10/2019 16:01 | Cheers Bermuda, thought I was going nuts for a moment. Good that those in an ISA can be moved. I hold in SIPP and trading account so it didn't come up for me. | waterloo01 | |
10/10/2019 15:55 | I was reading on the LSE. Bronxville says Novelion has been delisted from the Nasdaq on October 8th. How can arbitrage between the 2 shares happen if that is the case. | chica1 | |
10/10/2019 15:51 | webpax, maybe I'm wrong as you seem to have them in an ISA. I was sure I read they couldn't be. Will look but I might be wrong. | waterloo01 | |
10/10/2019 15:49 | webpax, I spoke to HL today, they'll be contacting shareholders within a week or so with arrangements for moving the CVRs out of their ISAs. You also should have received a message from HL outlining the terms of the CVRS and that also confirmed that they can't be held in an ISA. | bermudashorts | |
10/10/2019 15:42 | waterloo0110 Oct '19 - 08:41 - 5039 of 5044 0 0 0 Can't hold them in an ISA. They did make that clear. Where was this made clear waterloo01? I've had them credited to my Hargreaves Lansdown ISA, but nothing in my IG ISA yet. | webpax |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions